Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients

Johnson & Johnson (J&J)

Status and phase

Completed

Phase 4

Conditions

Visual Acuity

Treatments

Device: Control Eye Drops

Device: Test Eye Drops

Study type

Interventional

Funder types

Industry

Identifiers

NCT03466086

CR-6013

Details and patient eligibility

About

This clinical study is a randomized, double-masked, cross-over, bilateral, 2 treatment x 2 period, dispensing 4-visit study with a 7-9 day washout period in between visits 2 and 3. The study will last approximately 3 months.

Enrollment

57 patients

Sex

All

Ages

18 to 69 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Potential subjects must satisfy all the following criteria to be enrolled in the study:
1. Subjects must be at least 18 years of age and no more than 69 years of age (inclusive)
2. Subjects must be non-contact lens wearers
3. Subjects must have a DEQ-5 score of >6 at either Visit 0 (pre-screen) and/or Visit 1 (screening).
4. Subjects must achieve visual acuity of 20/30 (equivalent to 0.18 logMAR) or better in each eye, either unaided or best corrected.
5. Subjects must possess a functional/usable pair of spectacles and bring them to every visit (only if applicable - to the investigators discretion).
6. Subjects must read, understand, and sign the Statement of Informed Consent.
7. Subjects must appear able and willing to adhere to the instructions set forth in this clinical protocol
  
  Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
1. Currently pregnant or breast-feeding.
2. Diabetes.
3. Any ocular or systemic allergies or disease which may interfere with the clinical trial (at the investigator's discretion).
4. Any systemic disease, autoimmune disease, or use of medication which may interfere with the clinical trial (at the investigator's discretion).
5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report
6. Any Grade 3 or greater biomicroscopy findings (this includes, corneal edema, corneal staining, corneal vascularization, conjunctival injection, tarsal abnormalities, bulbar injection) on the FDA scale
7. Any active ocular abnormalities/conditions that may interfere with the clinical trial (this includes, but not limited to, chalazia, recurrent styles, pterygium, infection, etc)
8. Any corneal distortion due to previous rigid gas permeable lens wear, surgery or pathology
9. History of any ocular or corneal surgery (e.g. RK, PRK, LASIK)
10. Participation in any pharmaceutical or medical device related clinical trial within 14 days prior to study enrollment.
11. History of binocular vision abnormality or strabismus.
12. Habitual wearers of soft contact lenses in the past 1 month or rigid gas permeable lens within the past 3 months
13. Current habitual use of Prescription Only Medicines (POM) to treat dry eye or ocular discomfort, ocular steroids, or any medication (RX or OTC) that would interfere with the clinical study (at the discretion of the investigator).)
14. Employees of investigational clinic (investigator, coordinator, and technician etc) or family member of an employee of the clinical site by self-report.

In addition to the above criteria, patients with any allergy or sensitivity to ingredients that this product may contain (liposomes, sodium hyaluronate, vitamin E polyethylene glycol succinate (TPGS), polyethylene glycol 400 (PEG 400), disodium edetate, polyhexanide methylbiguanide, propylene glycol, boric acid, dimyristoyl phosphatidylglycerol, edetate disodium, hydroxypropyl guar, mineral oil, polyoxyl 40 sterate, polyquaternium-1, sorbitan tristearate, sorbitol, hydrochloric acid and/or sodium hydroxide) should not participate in the study.